Search
forLearn
4 / 4 resultslearn Cetirizine
popular antihistamine showing promise for hair loss as an anti-inflammatory and prostaglandin inhibitor
learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
Research
5 / 1000+ results![Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy](/images/research/ffc62b93-a2ce-4bbe-b820-674e35ef677a/small/25153.jpg)
research Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy
A woman's hair loss during treatment with specific hepatitis C drugs grew back after stopping the medication.
![Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege](/images/research/1bf92c53-1ce8-4a5f-91aa-09b4484b82d8/small/24392.jpg)
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
![Interferon alpha 2B](/images/research/b7a6a506-60a4-4a57-8b68-e490dd8aa427/small/25349.jpg)
research Interferon alpha 2B
Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.
![A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma](/images/research/0bc33b53-3800-453f-b867-ec78b089ea42/small/25053.jpg)
research A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma
Most patients treated with low-dose alpha-interferon for malignant melanoma experienced skin side effects, with hair loss being the most frequent.
![Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV](/images/research/240ab57f-a7d7-4591-b0be-0ab2dfa761cd/small/14067.jpg)
research Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV
A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
Community Join
5 / 116 resultscommunity Medications that cause extra hair growth
The post discusses the side effects of various drugs causing excess hair growth, questioning why only minoxidil is used in the hair loss industry. The conversation includes users sharing their experiences and concerns about potential side effects of these drugs, with some preferring baldness over potential health risks.
community 15 months on 0.5 mg fin only. This stuff works
A user shared progress pictures after 15 months on 0.5 mg finasteride, reporting significant hair regrowth starting around 9 months. They no longer see the need for a hair transplant.
community Most Recent Interesting Hairloss Studies: 10% Minox vs 5% Minox / Radio Rrequency Treatment for AA / Topical Ketoconazole / PRP+Minox vs Minox vs PRP / Alopecia as a systemic disease
Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.
community Winlevi coming out in 2019
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
community FCE 28260: A Forgotten 5α-Reductase Inhibition
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.